Novo Nordisk's go-to GLP-1 drug formulation, which uses semaglutide as the primary agonist, is increasingly being left behind in the weight loss efficacy race, overshadowed by the next-gen offerings from the likes of Eli Lilly and Company and VK Therapeutics. Now, a new study also raises the specter of suicidal ideation vis-a-vis Novo Nordisk's primary anti-diabetes and anti-obesity offering. GLP-1 Drugs: Risks Vs. Reward The GLP-1 drugs from the likes of Novo Nordisk and Eli Lilly and Company mimic the GLP-1 hormone that is released naturally in the gastrointestinal tract as a response to eating. The hormone increases the level […]
Read full article at https://wccftech.com/people-who-take-novo-nordisk-glp-1-drug-are-at-a-greater-risk-of-developing-suicidal-thoughts/
WccftechContinue reading/original-link]